Deep vein thrombosis related circRNA and application thereof

By discovering circRNAs related to deep venous thrombosis, primers and kits for fluorescence quantitative PCR are designed to achieve high specificity and sensitivity diagnosis of deep venous thrombosis, and solve the problem of difficulty in early diagnosis in the prior art.

CN118931905APending Publication Date: 2024-11-12JIANSHI MEDICAL PRODUCTS (NANTONG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411192724.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art lacks effective biomarkers for early diagnosis and treatment of deep venous thrombosis (DVT), resulting in increased difficulty in diagnosis and treatment and frequent misdiagnosis and misdiagnosis.

Method used

A circular RNA (circRNA) associated with deep venous thrombosis was discovered and provided as a diagnostic marker, and was detected by designing specific primers and fluorescence quantitative PCR kits to assist in the diagnosis of deep venous thrombosis.

Benefits of technology

This circRNA is expressed in DVT patients with high specificity and sensitivity, AUC 0.875, sensitivity of 90.0%, and specificity of 75.0%, providing a reliable method for the early diagnosis of deep venous thrombosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931905A_ABST
    Figure CN118931905A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of molecular heredity, in particular to circRNA related to deep vein thrombosis and application of circRNA. According to the circRNA related to the deep vein thrombosis provided by the invention, a cDNA (complementary deoxyribonucleic acid) sequence corresponding to the circRNA is as shown in SEQ ID NO. 1; a human circRNA molecule is found and has different degrees of differential expression in DVT patients, it is verified that the human circRNA molecule can serve as a deep vein thrombosis diagnosis marker and has high specificity and sensitivity, AUC is 0.875, sensitivity is 90.0%, specificity is 75.0%, the marker is convenient and easy to detect, and therefore the human circRNA molecule has wide application prospects in the aspects of clinical diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of molecular genetic technology, and in particular to a circRNA associated with deep vein thrombosis and a use thereof. Background Art

[0002] Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Studies have found that once pulmonary embolism occurs after the thrombus falls off in DVT patients, only 2 / 3 of the patients can survive for 30 days, and 1 / 4 will die suddenly. For patients who have already had DVT, up to 10% will develop severe post-thrombotic syndrome, and 30% of patients will relapse within 10 years. In view of the high incidence and mortality rate of DVT, coupled with the hidden onset of DVT and the lack of specific clinical manifestations, the diagnosis and treatment of DVT is more difficult, and it is easy to miss and misdiagnose. Therefore, in-depth research on the pathogenesis of VTE and the search for sensitive and specific VTE markers that can diagnose VTE early are undoubtedly of great clinical significance for timely and accurate diagnosis of VTE and improvement of its treatment plan.

[0003] Over the years, domestic and foreign scholars have made great progress in the discovery of reliable biomarkers that can predict DVT, which can be generally divided into three categories: one is coagulation-related markers, such as D-dimer, factor VIII, etc.; the second is inflammatory markers, such as P-selectin, inflammatory factors, cell membrane particles and white blood cell counts; the third is genetic factors and microRNA (microRNA, miRNA). Explore and clarify the relevant mechanisms that affect thrombosis, find the correct methods and paths for effective and reliable molecular diagnosis at the molecular level, and change the current state of no reliable early diagnostic molecular markers. At the same time, it can also open up another way to further study the molecular mechanism of venous thrombosis.

[0004] In recent years, non-coding RNA (ncRNA) has attracted widespread attention from researchers as an important regulatory factor. ncRNA is a type of RNA that does not encode proteins but can simultaneously regulate multiple genes in the body. It participates in post-transcriptional regulation of genes and important biological processes such as cell proliferation, differentiation, apoptosis, and aging. With the rapid development of second-generation sequencing technology and bioinformatics, following microRNA (miRNA) and long noncoding RNA (lncRNA), the study of RNA molecular structure and biological function has gradually shifted from miRNA to circular RNA (circRNAs). CircRNAs are generated during the RNA shearing process and are closed loops. They are endogenous non-coding RNAs that are widely present in eukaryotic cells, have high stability, are evolutionarily conservative, and have cell and tissue specificity. Compared with linear RNA, circRNAs have a more stable structure and are not easily degraded by RNases. Its special molecular structure enables it to act as a miRNA "sponge", regulate transcription or shearing, interact with RNA-binding proteins, and participate in gene expression regulation. It has broad application prospects in clinical diagnosis and treatment. At present, there are no reports on circRNAs related to deep vein thrombosis, especially the application of circRNAs in the diagnosis or treatment of deep vein thrombosis. Summary of the invention

[0005] Therefore, the technical problem to be solved by the present invention is to provide a circRNA related to deep vein thrombosis and its use.

[0006] To this end, the present invention provides the following technical solutions:

[0007] A circRNA associated with deep vein thrombosis, wherein the cDNA sequence corresponding to the circRNA is shown in SEQ ID NO.1.

[0008] The use of the circRNA as a marker of deep vein thrombosis in the preparation of a product for auxiliary diagnosis or diagnosis of deep vein thrombosis.

[0009] Optionally, the product includes a detection reagent, a kit, a primer or a probe.

[0010] Primers used to detect the circRNA include primers designed based on the circRNA.

[0011] Optionally, the primers include primers for fluorescent quantitative PCR.

[0012] Optionally, the primers for the fluorescent quantitative PCR include a forward primer and a reverse primer, and the nucleotide sequences thereof are shown in SEQ ID NO.2 and SEQ ID NO.3, respectively.

[0013] A kit for assisting diagnosis or diagnosing deep vein thrombosis, comprising the primers of the circRNA.

[0014] Optionally, the following fluorescence quantitative PCR reaction system is also included:

[0015]

[0016] A device for assisting in the diagnosis or diagnosis of deep vein thrombosis, comprising:

[0017] RNA extraction unit, used to extract RNA from samples;

[0018] A reverse transcription unit, used for reverse transcribing the extracted RNA into cDNA;

[0019] The fluorescent quantitative PCR detection unit is used to detect the cDNA.

[0020] A method for detecting circRNA associated with deep vein thrombosis as a non-disease diagnosis method comprises using the primers for detecting the circRNA or the kit for auxiliary diagnosis or diagnosis of deep vein thrombosis to perform fluorescence quantitative PCR, wherein the reaction procedure of the fluorescence quantitative PCR is as follows:

[0021]

[0022] The technical solution of the present invention has the following advantages:

[0023] The present invention provides a circRNA associated with deep vein thrombosis, and the cDNA sequence corresponding to the circRNA is shown in SEQID NO.1; the present invention discovered a human circRNA molecule, which is differentially expressed to varying degrees in DVT patients, and has been verified to be a diagnostic marker for deep vein thrombosis with high specificity and sensitivity, AUC 0.875, sensitivity 90.0%, and specificity 75.0%. The detection of the marker is convenient and easy to operate, and thus has broad application prospects in clinical diagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 is the RNA electrophoresis gel image of each sample in Example 1 of the present invention;

[0026] Figure 2 is the relative expression level of hsa_circ_0007516 in 16 blood samples in Example 1 of the present invention; D refers to the DVT group (deep vein thrombosis group), and N refers to the experimental control group;

[0027] Figure 3 is the relative expression level of hsa_circ_0007516 in 40 blood samples in Example 2 of the present invention; D refers to the DVT group (deep vein thrombosis group), and N refers to the experimental control group;

[0028] Figure 4 It is the diagnostic efficacy of hsa_circ_0007516 alone in peripheral blood in Example 2 of the present invention;

[0029] Figure 5 It is the cyclization site of hsa_circ_0007516 in Circbase in Example 1 of the present invention;

[0030] Figure 6 is the map of the recombinant vector constructed in Example 3 of the present invention;

[0031] Figure 7 This is the plasmid gradient dilution qPCR melting curve in Example 3 of the present invention;

[0032] Figure 8 qPCR amplification curves of plasmid standards with different concentration gradients in Example 3 of the present invention;

[0033] Fig. 9 is the CT value corresponding to the qPCR amplification reaction of the plasmid standard products with different concentration gradients in Example 3 of the present invention;

[0034] Fig.10 is the standard curve in Example 3 of the present invention;

[0035] Fig.11 The random sample gradient dilution qPCR test results in Example 3 of the present invention;

[0036] Fig.12It is the CT value corresponding to the qPCR amplification reaction of the random sample gradient dilution in Example 3 of the present invention. DETAILED DESCRIPTION

[0037] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0038] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0039] The experimental materials and equipment used in the following examples are:

[0040] RNase free pipette tips, Axygen;

[0041] RNase free EP tube, Axygen;

[0042] Refrigerated centrifuge, Lu Xiangyi, Shanghai;

[0043] 96-well plate, Axygen;

[0044] Blood RNA extraction kit, Guangzhou Meiji R4168-03;

[0045] HiScript III 1st Strand cDNA Synthesis Kit (+gDNA wiper), Novozymes;

[0046] Universal Probe qPCR Master Mix, Biosharp;

[0047] Real-time fluorescence quantitative PCR instrument, Qtower3G;

[0048] SuperRT III All-in-one RT Mix with gDNA Remover, Beijing Lanjieke;

[0049] 2xUniversal SYBR qPCR Mix, Biosharp;

[0050] Real-time fluorescence quantitative PCR instrument, Qtower3G;

[0051] Gold Medal Mix V2, Qingke;

[0052] In-Fusion One-Step Kit, Yisheng;

[0053] Endonuclease, NEB;

[0054] Competent cells, Qingke;

[0055] Gel recovery kit, Qingke;

[0056] Low endotoxin plasmid extraction kit, Meiji;

[0057] Electrophoresis instrument, Shanghai Tianneng;

[0058] PCR instrument, Beijing Dongshenglong ETC811.

[0059] Example 1

[0060] 1. Expression of human homologous circRNA

[0061] qPCR detected the expression of circular RNAhsa_circ_0007516 (the cDNA sequence corresponding to the circRNA is shown in SEQ ID NO.1) in the peripheral blood of human DVT patients.

[0062] The samples were grouped as follows:

[0063] Deep vein thrombosis group (DVT group): The patients included in the study were outpatients or inpatients who visited the Affiliated Hospital of Nantong University. A comprehensive diagnosis method was used to determine deep vein thrombosis, including risk factor assessment, clinical manifestations, auxiliary examinations (color Doppler ultrasound, D dimer, DSA), etc. There were 28 specimens in the DVT group, recorded as D1 to D28, for backup.

[0064] Experimental control group (N group): Inpatients without deep vein thrombosis in both lower extremities confirmed by color Doppler ultrasound examination of the lower extremities. Patients with pregnancy, hypertension, hyperlipidemia, diabetes, tumors, immune system diseases, systemic inflammatory response syndrome and active infection, as well as genetic history of thrombotic diseases, history of cardiovascular and cerebrovascular diseases and family history were excluded. The specimens were from legal sources. There were 28 specimens in the control group, recorded as N1 to N28, for backup.

[0065] 2. RNA Extraction

[0066] First, 8 cases in each of the DVT group and N group were tested to verify whether the circular RNA hsa_circ_0007516 was expressed in the peripheral blood of human DVT patients. According to the instructions of Guangzhou Meiji Biotechnology Blood RNA Extraction Kit, the RNA integrity was detected by electrophoresis after RNA extraction, and the RNA concentration was detected by ultra-micro spectrophotometer. The concentrations of each sample are shown in Table 1.

[0067] Table 1. Concentration of each sample

[0068]

[0069] 3. Reverse transcription

[0070] Primer design

[0071] Primers were provided by reverse transcription kit (SuperRT 1-tube reverse transcription kit (including gDNA enzyme), Beijing Lanjieke Technology Co., Ltd.)

[0072] 3.2. Prepare the first-strand cDNA synthesis reaction solution (see Table 2). After preparation, gently pipette and mix.

[0073] Table 2. First-strand cDNA synthesis reaction solution

[0074]

[0075]

[0076] 3.3. The first-strand cDNA synthesis reaction was carried out according to the following conditions (see Table 3). The electrophoresis gel images of RNA samples are as follows: Figure 1 shown.

[0077] Table 3. First-strand cDNA synthesis reaction conditions

[0078]

[0079] * If the template has complex secondary structure or high GC region, increasing the reaction temperature to 55°C may help improve the yield.

[0080] 4. qPCR experiment

[0081] a. Fluorescence quantitative PCR: The reverse transcribed cDNA was used as a template for fluorescence quantification, and primers were designed based on the cDNA sequence of the circRNA (hsa_circ_0007516) associated with deep vein thrombosis (as shown in SEQ ID NO.1). Primers were designed according to the circular RNA primer design principle (cross-splicing site design), and GAPDH was used as an internal reference. The primers are as follows, and the fluorescence quantitative PCR reaction system is shown in Table 4.

[0082] Forward primer: 5'-GCCCCTCCAAACAGTAGAAGT-3' is shown in SEQ ID NO:2.

[0083] Reverse primer: 5'-CTGTATGATCCAAATCCGGGGT-3' as shown in SEQ ID NO:3.

[0084] Table 4. Fluorescence quantitative PCR reaction system

[0085] 2×SYBR qPCR Mix 10μl Forward primer (10 μM) 0.5μl Reverse primer (10 μM) 0.5μl Template DNA, concentration 800ng / μl 1μl Sterile distilled water Make up to 20 μl

[0086] b.qPCR reaction program settings

[0087] Table 5. qPCR reaction procedure

[0088]

[0089]

[0090] 5. qPCR Data Processing

[0091] According to 2 -△△C t The formula calculates the expression of the target gene:

[0092] Set Ct A1 is the Ct value of the target gene in sample 1, Ct B1 is the Ct value of the internal reference gene of sample 1; Ct A2 is the Ct value of the target gene in sample 2, Ct B2 is the Ct value of the reference gene in sample 2, then the expression level ratio of the target gene in sample 1 and sample 2 can be roughly calculated as (2 -△△Ct Law):

[0093] △△Ct=(Ct A2 -Ct B2 )-(Ct A1 -Ct B1 )=X

[0094] Then the expression level of the target gene in sample 2 is 2 times that in sample 1. -X times.

[0095] Table 6. Relative expression of hsa_circ_0007516 in 16 blood samples

[0096] sample D1-8 sample N1-8 D1 1 N1 0.529731547 D2 0.65823136 N2 0.715322966 D3 0.819793998 N3 0.649169294 D4 0.98851402 N4 0.801069878 D5 0.743978757 N5 0.461158097 D6 0.399610575 N6 0.422395587 D7 0.831237896 N7 0.723634619 D8 1.143402487 N8 0.585064127

[0097] The results are shown in Table 6 and Figure 2 As shown in the figure, the relative expression level of hsa_circ_0007516 in the deep vein thrombosis group was significantly higher than that in the control group (p < 0.05). It was found that hsa_circ_0007516 had differences between the DVT group (group D in the figure) and group N, indicating that hsa_circ_0007516 (cDNA sequence such as SEQ ID NO.1) can be used as a diagnostic marker for deep vein thrombosis.

[0098] Example 2

[0099] This example provides a method for diagnosing deep vein thrombosis, and examines the diagnostic effect of hsa_circ_0007516 (cDNA sequence such as SEQ ID NO.1) in Example 1 as a diagnostic marker for deep vein thrombosis.

[0100] 1. Sample;

[0101] Deep vein thrombosis group (DVT group): same as in Example 1, samples were selected from D9 to D28;

[0102] The experimental control group (N group) was the same as in Example 1, and samples N9-N28 were selected.

[0103] 2. RNA Extraction

[0104] The RNA in the peripheral blood of each sample was extracted using the instructions of the Guangzhou Meiji Biotechnology Blood RNA Extraction Kit in step "2. RNA Extraction" in Example 1.

[0105] 3. Reverse transcription

[0106] The RNA extracted from the peripheral blood of each sample was reverse transcribed into cDNA using the same method as "3. Reverse transcription" in Example 1.

[0107] 4. qPCR detection

[0108] The method is the same as "4. qPCR experiment" in Example 1.

[0109] 5. qPCR Data Processing

[0110] The method is the same as "5. qPCR data processing" in Example 1.

[0111] The relative expression results of hsa_circ_0007516 in the DVT group and the N group are shown in Figure 3 As shown, the sample was expanded to detect the expression of this indicator in the DVT group (n = 20) and the N group (n = 20). The results showed that after the sample was expanded, the expression of hsa_circ_0007516 in the two groups was more obvious (p < 0.001). Based on the receiver operating characteristic (ROC) analysis, the ROC curve analysis showed that the expression level of hsa_circ_0007516 was statistically significant between the deep vein thrombosis group and the control group (p < 0.001) ( Figure 4 ), with an AUC (95% IC) of 0.875 (0.767, 0.983), a sensitivity of 90.0%, and a specificity of 75.0%, indicating that hsa_circ_0007516 has a good diagnostic value for deep vein thrombosis.

[0112] Example 3

[0113] 1. Plasmid construction

[0114] 1. PCR amplification of target fragment

[0115] Using the cDNA obtained in "3. Reverse transcription" in Example 1 as a template, PCR amplified a sequence containing a partial sequence of hsa_circ_0007516 and a cyclization site, with a total length of 130 bp. The target sequence was:

[0116] GCCCCTCCAAACAGTAGAAGTAGAAACCCCAAGGAGATGACTTAC AGTCTCTTCTGTTTCACTTTTTGGATGAATGGCTTTATAAGTTCAGTGC TGATGAAT TCTTCATACCCCGGATTTGGATCATACAG , as shown in SEQ ID NO: 6. (TCTTCATACCCCGGATTTGGATCATACAG in the above underlined sequence is the cyclization site of hsa_circ_0007516, as shown in SEQ ID NO: 7, as shown in Figure 5 shown).

[0117] The gene was ligated into pcDNA3.1+ by infusion homologous recombination.

[0118] The sequences of the homologous recombination primers are as follows:

[0119] C7516-F: 5'-cttggtaccgagctcggatccGCCCCTCCAAACAGTAGAAGTAGA-3' is shown in SEQ ID NO: 4.

[0120] C7516-R: 5′-tgctggatatctgcagaattcCTGTATGATCCAAATCCGGGG-3′ is shown in SEQ ID NO:5.

[0121] PCR amplification reaction program: 98°C for 5 min, 38 cycles (98°C for 10 s, 58°C for 30 s, 68°C for 60 s), 68°C for 5 min, and storage at 4°C. The reaction system is shown in Table 7.

[0122] Table 7. PCR amplification reaction system

[0123] Reagents volume Gold Medal Mix 22μL C7516-F(10μM) 1μL C7516-R(10μM) 1μL Template (cDNA) (500ng) 1μL <![CDATA[ddH2O]]> Up to 25μL

[0124] Note: For non-natural sequences or genes without bands amplified by PCR, the target gene fragments are synthesized by whole gene synthesis.

[0125] 2. PCR amplification product recovery

[0126] Gel recovery was performed according to the instructions of the gel recovery kit and the PCR product was stored at -20°C.

[0127] 3. Double restriction digestion of empty vector

[0128] Add endonucleases to the empty vector for double digestion. The reaction system is shown in Table 8 and maintained at 37°C for 1 hour. Then cast 1.5% agarose gel for electrophoresis and recover the target band.

[0129] Table 8 Double enzyme digestion reaction system

[0130]

[0131]

[0132] 4. In-Fusion Connection

[0133] Refer to the instructions for one-step infusion homologous recombination to prepare the ligation reaction solution, maintain at 50°C for 20 min, and then transform or store at -20°C.

[0134] Table 9 Ligation reaction system

[0135] Reagents volume PCR products 10-200ng Empty vector digestion product 50-200ng 5X In-Fusion HD Enzyme Premix 10μL <![CDATA[ddH2O]]> Make up to 20 μL

[0136] 5. Transformation of Competent Cells

[0137] (1) Take out the competent cells from the -80°C refrigerator and thaw them on ice;

[0138] (2) Aseptically take 50 μL of competent cells and place them in a sterilized 1.5 mL centrifuge tube;

[0139] (3) Add 10 μL of ligation product and place on ice for 30 minutes;

[0140] (4) Place at 42°C for 30 seconds (heat shock) without shaking the centrifuge tube;

[0141] (5) Quickly transfer the centrifuge tube to ice and place it for 2 to 3 minutes;

[0142] (6) Add 200 μL LB liquid culture medium, mix well by pipetting, spread on LA agar plate, and culture inverted at 37°C for 12 to 16 h.

[0143] 6. Identification

[0144] PCR identification of positive colonies: Pick a single colony and inoculate it in LA culture medium, culture it at 37℃ and 220rpm for 4h, then take 1μL of the culture medium as a template for PCR amplification. Then pour 1.5% agarose gel and take 5μL of PCR product for electrophoresis detection.

[0145] Positive bacterial liquid sequencing identification: The positive bacterial liquid detected by bacterial liquid PCR is sequenced, and the obtained results are subjected to BLAST sequence comparison analysis to determine whether it is the target gene. The constructed vector sequence is as follows Figure 6 shown.

[0146] 7. Endotoxin-free plasmid extraction

[0147] Endotoxin-free plasmids were extracted according to the instructions of Meigi low-endotoxin plasmid extraction, and the plasmids were stored at -20°C.

[0148] 2. qPCR detection

[0149] Reference Example 1

[0150] A. qPCR reaction system preparation (see Table 10)

[0151] Table 10. Fluorescence quantitative PCR reaction system

[0152] 2×SYBR qPCR Mix 10μl Forward primer (10 μM) 0.5μl Reverse primer (10 μM) 0.5μl Template DNA, concentration 800ng / μl 1ul Sterile distilled water Make up to 20 μl

[0153] B.qPCR reaction program settings (see Table 11)

[0154] Table 11. qPCR reaction procedure

[0155]

[0156] 3. Preparation of standard curve

[0157] 1. Preparation of standard products

[0158] The plasmid samples were diluted 10-fold to prepare the standard. 0 , 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 copies / ml.

[0159] 2. Standard curve drawing

[0160] Using standards of different concentrations as templates, at least 3 technical replicates were performed for each standard, and qPCR amplification was performed simultaneously (following the above step 2, qPCR detection). The qPCR melting curve and qPCR amplification curve were as follows: Figure 7 and Figure 8 After the reaction is completed, the CT values ​​corresponding to the standard samples with different concentrations are obtained, as shown in Fig. 9 As shown in the figure, generate a standard curve in the EXCEL table.

[0161] Results: The sequencing peak graph was normal, without impurity peaks or overlapping bands, and the sequence comparison was consistent, indicating that the target sequence was successfully inserted into pcDNA3.1+ and the vector was successfully constructed.

[0162] The results of vector sequence sequencing are shown in SEQ ID NO: 8:

[0163] CCGGAGGGGGAGTTTATAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCGCCCCTCCAAACAGTAGAAGTAGAAACCCAAGGAGATGACTTACAGTCTCTTCTGTTTCACTTTTTGGATGAATGGCTTTATAAGTTCAGTGCTGATGAATTCTTCATACCCCGGATTTGGATCATACAGGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTTATAAAGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGGTGTTGTTCAAGTAAGGGGGGTTGGAAAGTTTTTTTAAGGCGTTTCTAAGACAAAGGCAGGGAGGTTA (italics indicate restriction site; bold indicates target sequence). NCBI Blast comparison analysis showed that the hsa_circ_0007516-130bp target sequence was 100% linked to the vector, and the vector was successfully constructed.

[0164] The plasmid samples were diluted in a 10-fold concentration gradient, and the CT value of each concentration standard was detected by real-time quantitative PCR. The standard curve was prepared with the CT value as the ordinate and the logarithm of the plasmid sample copy number as the abscissa. The curve correlation coefficient R 2 =0.9905, indicating that the plasmid has a good linear relationship within the dilution concentration range, and the regression equation is y=-3.4704x+51.496. The standard curve is shown in Fig.10 shown.

[0165] 3. Repeatability test

[0166] 20 serum samples (serum samples were from the Affiliated Hospital of Nantong University, outpatients or inpatients with deep vein thrombosis in the Affiliated Hospital of Nantong University) were tested for copy number twice

[0167] According to the known CT value through the standard curve ( Fig.10 ) Calculate the copy number of the sample. As can be seen from the following table, the copy number of the two repeated samples is not much different (refer to the qPCR method in Example 1).

[0168] Table 12. Copy number of samples

[0169]

[0170]

[0171] 4. Sensitivity detection

[0172] Random samples (samples in the DVT group in Example 1, randomly selected) were subjected to serial dilution qPCR detection (refer to the qPCR method in Example 1).

[0173] The same sample was diluted 10 times in series, and the final dilution was 104 No CT ( Fig.11 and Fig.12 ).

[0174] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. circRNAs associated with deep vein thrombosis, It is characterized in that The cDNA sequence corresponding to the circRNA is shown in SEQ ID NO.

1.

2. Use of the circRNA according to claim 1 as a marker for deep vein thrombosis in the preparation of a product for auxiliary diagnosis or diagnosis of deep vein thrombosis.

3. The use according to claim 2, It is characterized in that The products include detection reagents, kits, primers or probes.

4. A primer for detecting the circRNA according to claim 1, It is characterized in that Including primers designed based on the circRNA.

5. The circRNA primer according to claim 4, It is characterized in that The primers include primers for fluorescent quantitative PCR.

6. The circRNA primer according to claim 5, It is characterized in that The primers for the fluorescent quantitative PCR include a forward primer and a reverse primer, and the nucleotide sequences thereof are shown in SEQ ID NO.2 and SEQ ID NO.3 respectively.

7. Kits for assisting diagnosis or diagnosing deep vein thrombosis, It is characterized in that A primer comprising the circRNA according to any one of claims 4 to 6.

8. The kit for assisting diagnosis or diagnosing deep vein thrombosis according to claim 7, It is characterized in that It also includes the following fluorescent quantitative PCR reaction system:

9. A device for assisting in the diagnosis or diagnosis of deep vein thrombosis, It is characterized in that include: RNA extraction unit, used to extract RNA from samples; A reverse transcription unit, used for reverse transcribing the extracted RNA into cDNA; The fluorescent quantitative PCR detection unit is used to detect the cDNA.

10. A method for detecting circRNA associated with deep vein thrombosis as a non-disease diagnostic method. It is characterized in that The method comprises using the primers for detecting the circRNA according to claim 4, 5 or 6 or the kit for assisting diagnosis or diagnosing deep vein thrombosis according to claim 7 or 8 to perform fluorescence quantitative PCR, wherein the reaction procedure of the fluorescence quantitative PCR is as follows: